Trials / Terminated
TerminatedNCT03256630
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study To Evaluate A Blood Biomarker That Can Distinguish Between the Presence Or Absence of Aggressive Prostate Cancer
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 128 (actual)
- Sponsor
- Genomic Health®, Inc. · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
Detailed description
The over-arching goal of this study is to evaluate if biomarkers within the blood or urine of men with localized prostate cancer can distinguish between those with indolent cancer, defined as Gleason Grade Groups 1 and 2 and those with more aggressive disease (Gleason Grade Groups 3, 4, and 5).
Conditions
Timeline
- Start date
- 2018-01-10
- Primary completion
- 2018-12-20
- Completion
- 2019-02-28
- First posted
- 2017-08-22
- Last updated
- 2020-02-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03256630. Inclusion in this directory is not an endorsement.